Literature DB >> 31326950

Ultrasound features and clinical outcome of patients with malignant ovarian masses diagnosed during pregnancy: experience of a gynecological oncology ultrasound center.

Francesca Moro1, Floriana Mascilini, Tina Pasciuto2, Martina Leombroni2, Marta Li Destri2, Ilaria De Blasis2, Serafina Garofalo2, Giovanni Scambia2, Antonia Carla Testa2.   

Abstract

OBJECTIVE: The number of women diagnosed with ovarian masses during pregnancy has increased in recent years and the management of these women can be controversial. We aim to describe ultrasound characteristics and clinical outcomes of patients with malignant ovarian masses diagnosed during pregnancy.
METHODS: Patients with a histological diagnosis of malignant ovarian mass detected during pregnancy who underwent pre-operative ultrasound by experienced ultrasound examiners between December 2000 and November 2017 were included in this retrospective observational study. Ultrasound characteristics of the masses were described using International Ovarian Tumor Analysis terminology. Patients with ovarian masses but without histopathological reports were excluded. Results are presented as absolute frequency (percentage) for nominal variables and as median (range) for continuous variables. Results A total of 22 patients were included in the analysis. The median age was 32.5 (range 23-42) years and median gestational age at diagnosis was 13.5 (range 4-30) weeks. Eight (36.4%) patients had a serous/endocervical-type borderline tumor, seven (31.8%) patients had a primary epithelial ovarian carcinoma, five (22.8%) patients had a metastatic tumor to the ovary, and two (9%) patients had a mucinous borderline tumor. At ultrasound, mucinous borderline tumors were multilocular (1/2, 50%) or multilocular-solid (1/2, 50%) lesions. Serous/endocervical-type borderline tumors were unilocular-solid (3/8, 37.5%) or multilocular-solid (5/8, 62.5%) masses and all had papillary projections. Most invasive epithelial ovarian cancers were multilocular-solid masses (5/7, 71.4%). All metastatic tumors appeared as solid masses. No patients with borderline tumors had a cesarean section due to disease, whereas most patients with epithelial ovarian carcinomas (4/7, 57.2%) and with ovarian metastases (3/5, 60%) had a cesarean section due to disease. No neonatal complication was reported for patients with borderline tumors or epithelial ovarian carcinomas, whereas two of three newborns of patients with metastatic tumor died of the disease.
CONCLUSION: At ultrasound, morphological features of malignant ovarian masses detected during pregnancy are similar to those described in non-pregnant patients. The likelihood of undergoing cesarean section increases with malignant disease in the ovary. © IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  ovarian carcinoma; ovarian neoplasms; personalised diagnostics; pregnancy; ultrasonography

Mesh:

Year:  2019        PMID: 31326950     DOI: 10.1136/ijgc-2019-000373

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  4 in total

1.  Psychological Nursing Effect of Patients with Gynecological Malignant Tumor.

Authors:  Hui Wang; Xitao Gao; Na Chen
Journal:  Biomed Res Int       Date:  2022-05-23       Impact factor: 3.246

2.  Sonographic Assessment of Complex Ultrasound Morphology Adnexal Tumors in Pregnant Women with the Use of IOTA Simple Rules Risk and ADNEX Scoring Systems

Authors:  Artur Czekierdowski; Norbert Stachowicz; Agata Smoleń; Tomasz Kluz; Tomasz Łoziński; Andrzej Miturski; Janusz Kraczkowski
Journal:  Diagnostics (Basel)       Date:  2021-02-28

Review 3.  Efficacy and Safety of Platinum-Based Chemotherapy for Ovarian Cancer During Pregnancy: A Systematic Review and Meta-Analysis.

Authors:  Yaping Pei; Yuanfeng Gou; Na Li; Xiaojuan Yang; Xue Han; Liu Huiling
Journal:  Oncol Ther       Date:  2021-12-04

Review 4.  Primary and recurrent serous borderline tumors during pregnancy: a case report and literature review.

Authors:  Aya Matsumoto; Takuma Ito; Fumika Hamaguchi; Maya Kasuga; Teppei Mikami; Mayo Hino; Reiko Yokoyama; Shogo Yamamura; Harumi Sakata; Sachiko Minamiguchi; Masaki Mandai; Takaaki Yoshida
Journal:  Int Cancer Conf J       Date:  2021-02-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.